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Cisplatin is a chemotherapeutic drug but induces acute kidney injury (AKI). Cisplatin-induced AKI de-
pends on several signaling pathways leading to apoptosis in tubular epithelial cells. Glutamine is a
substrate for the synthesis of glutathione, the most abundant intracellular thiol and antioxidant, and
plays an important role in protecting cells from apoptosis induced by different stimuli. In the present
study, we investigated the protective effect of glutamine on cisplatin-induced AKI. Rats were divided into
control, glutamine, cisplatin, and cisplatin plus glutamine groups. Glutamine ameliorated renal
dysfunction, tissue injury, and cisplatin-induced apoptosis. Cisplatin increased cell death, caspase-3
cleavage, activation of MAPKs and p53, oxidative stress, and mRNA expression of TNF-a and TNFR1 in
HK-2 cells. Glutamine treatment reduced cisplatin-induced these changes in HK-2 cells. Notably, gluta-
mine reduced the cisplatin-induced expression of organic cation transporter 2 (OCT2) and cisplatin
accumulation. Our results suggest that the protective effect of glutamine on cisplatin is speciﬁc for
proximal tubular cells and the initial effects may be related to attenuation of cisplatin uptake. Thus,
glutamine administration might represent a new strategy for the treatment of cisplatin-induced AKI.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cisplatin is one of the most effective and potent anticancer
drugs for the treatment of solid tumors such as those in lung, head
and neck, ovarian, and testicular cancer (1). Acute kidney injury
(AKI), however, is the main side effect observed after cisplatin
treatment. Indeed, this side effect has limited the clinical use of
cisplatin in 25e30% of patients, even after the ﬁrst dose. Although
nephrotoxicity is a serious consequence of aggressive therapy withepartment of Internal Medi-
ongsang National University,
c of Korea. Tel.: þ82 55 750
acological Society.
. Production and hosting by Elsecisplatin, the mechanism by which cisplatin selectively damages
proximal tubule cells remains unclear (2). While multiple mecha-
nisms have been documented to contribute to cisplatin nephro-
toxicity, how these signaling pathways are integrated to induce
renal pathology is largely unknown (3). Several investigators have
demonstrated that cisplatin induces oxidative stress in renal
epithelial cells primarily by decreasing antioxidant enzyme activity
and depleting intracellular concentrations of glutathione (4,5).
Numerous studies have now documented the beneﬁcial effects of
various antioxidants in cisplatin-induced nephrotoxicity.
Glutamine is a nonessential amino acid, but it is heavily used
as a major metabolic fuel as well as a precursor for nucleotide
synthesis in ﬁbroblasts, lymphocytes, and macrophages (6). It has
long been known that, under certain physiological circumstances,
glutamine serves as a major fuel for the gut, kidney, and immune
system. Many cultured mammalian cells use glutamine, within thevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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meet energetic and biosynthetic needs (7e10). Glutamine is also a
substrate for the synthesis of glutathione (GSH), the most abundant
intracellular thiol and antioxidant (11). Thus, the antioxidant
properties of glutamine could contribute to beneﬁcial effects in
cells experimentally (12) and glutamine might play an important
role in protecting cells from apoptosis induced by different stimuli.
Tubular damage is recognized as a major pathogenic factor in
cisplatin-induced nephrotoxicity. The highest concentration of
cisplatin in the kidney is reached in the proximal tubule, where
cisplatin leads to renal toxicity, tubular injury, and cell death, time
and dose dependently (13,14). Research has revealed multiple
signaling pathways that are responsible for tubular cell injury and
death during cisplatin nephrotoxicity (3,15). Thus, proximal tubule
cell death is considered to be the major pathophysiological mech-
anism underlying cisplatin nephrotoxicity and AKI and is a limiting
factor for the clinical use of cisplatin (3). Renal tubular cell death
after in vitro exposure to cisplatin has been well documented
(16,17). However, much less is known concerning the mechanism
underlying cisplatin uptake by tubular cells. High sensitivity of
tubular cells to cisplatin is partly attributed to the high uptake of
cisplatin by these cells.
The kidney is one of the most important organs for maintaining
the homeostasis of organic cations (18). Naþ-independent poly-
speciﬁc organic cation transporters (OCTs) have been postulated for
epithelia in the intestine, liver, kidney, and the brain (19). Regula-
tion of OCTs is important for the secretion of multiple cationic
endogenous substances, drugs, and other xenobiotics. A common
feature of OCTs is the presence of several potential protein kinase
phosphorylation sites in the intracellular loops, suggesting that
their activity can be regulated. OCT2 is the main OCT in the human
kidney (20) and is located in the basolateral membrane in the
proximal tubules (21). Both basolateral OCT1 and OCT2 and the
copper transporter (Ctr1) are involved in cisplatin transport,
accumulation, and toxicity (22,23). Unfortunately, few studies have
reported that antioxidants are involved in cisplatin uptake in a
cisplatin-induced nephrotoxicity model.
Multiple pathways are responsible for tubular cell apoptosis
during cisplatin-induced nephrotoxicity and spontaneous inhibi-
tion of those pathways is usually necessary for global therapeutic
effects. Although many in vivo and in vitro studies have been pro-
posed to reduce cisplatin-induced nephrotoxicity (24e27), the
protection is partial, highlighting the need for combined or novel
strategies. Thus, alternative strategies are needed that are less toxic
that produce more global therapeutic effects. The aim of the pre-
sent study was to evaluate the role of glutamine as a protective
agent against cisplatin-induced cytotoxicity in vivo and in vitro.
2. Materials and methods
2.1. Animal treatment
Animal studies were conducted according to the Gyeongsang
National University Guide for Care and Use of Laboratory Animals.
Male Sprague Dawley rats (200e230 g) were maintained in a 12/
12-h light/dark cycle in a temperature- and humidity-controlled
facility. Standard rat chow and water were provided ad libitum.
Animals were divided into four groups. The control group received
a single injection of saline, intraperitoneally (n ¼ 3). The glutamine
group received a single subcutaneous injection of glutamine (1 g/kg
body weight) (n ¼ 3). The cisplatin group received a single intra-
peritoneal injection of cisplatin (10 mg/kg body weight) and then
an equal volume of phosphate-buffered saline (PBS) instead of
glutamine (n ¼ 10). The cisplatin plus glutamine group ﬁrst
received cisplatin, and then glutamine at day 1 after cisplatininjection (n¼ 10). All animals were sacriﬁced at day 3 after cisplatin
injection. Blood and tissue samples were collected for analysis of
renal function and tissue damage.
2.2. Assessment of renal function
Serum samples were examined for blood urea nitrogen (BUN)
and serum creatinine (Bayer, Pittsburgh, PA) in an Autoanalyzer
using standard diagnostic kits.
2.3. Renal histology and damage scoring
Sections (5 mm)were stainedwith hematoxylin and eosin. Tubular
injury was deﬁned as tubular epithelial necrosis, cast formation,
intratubular debris, and loss of the brush border. Tubular injury was
scored by grading the percentage of affected tubules under 400
magniﬁcation: 0, 0%; 0.5,<10%; 1,10e25%; 2, 26e50%; 3, 51e75%; and
4, 75e100%. To score injured tubules,whole tubular numbers perﬁeld
were considered to be standard under 400 magniﬁcation. The
gradingpercentagewascalculated ineachﬁeldas follows; injuryscore
(%)¼ (number of injured tubules/number of whole tubules) 100. At
least 10 areas in the cortex per slide were randomly selected.
2.4. Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay
Detection of DNA fragmentation was performed using a com-
mercial kit (Roche, Indianapolis, IN). Semi-quantitative analysis
was performed by counting the number of TUNEL-positive cells per
ﬁeld, in renal tissue, at 400 magniﬁcation. At least 10 areas in the
cortex per slide were randomly selected.
2.5. Cell culture
HK-2 human kidney proximal tubular cells (American Type
Culture Collection, Manassas, VA) were cultured in renal epithelial
basal medium (GIBCO BRL, Grand Island, NY) with manufacture-
provided supplements and were subcultured using a 0.05% tryp-
sineEDTA solution (GIBCO BRL). Cells were incubated with various
concentrations of cisplatin or vehicle (PBS) for 15, 30, 60, or 120min
with PBS or glutamine, and then were used for various analyses,
such as cell viability assays, measurement of cellular GSH, reverse
transcription-polymerase chain reaction (RT-PCR), immunoblot-
ting, and mitochondrial damage assays.
2.6. RT-PCR
Total RNA was extracted from HK-2 cells using the TRIzol
method according to the manufacturer's protocol (GIBCO BRL).
Equal amounts (5 mg) of DNA-free total RNA from each sample were
converted to cDNA using 200 U of SuperScript II RT (GIBCO BRL) in a
20 mL reaction volume. Reverse transcription was performed using
the following conditions: 22 C for 10 min, followed by 42 C for
45 min, and ﬁnally 95 C for 5 min. Reaction products (2.0 mL) were
subjected to PCR ampliﬁcation using 1.25 U of Taq DNA polymerase
(Promega, Madison, WI) in a 50 mL reaction volume. Primer se-
quences for RT-PCR are followings; TAAAGATAATGACCACATCGC
(sense) and TATGATGTTTAACCAGTGCAGG (antisense) for OCT-1,
AGTTGCCTATACAGTTGGGCTC (sense) and CAGGGCAGAGTAG
AAATCC (antisense) for OCT-2, GACCAAGGATTTGAGAAAGTTG
(sense) and AGGGAATCTGTGGCTCTACG (antisense) for OCT-3, G
ACAAGCCTGTAGCCCATGTTGTA (sense) and CAGCCTTGGCCCTTG
AAGA (antisense) for TNF-a, GACTGGTTCCTTCTCTTGGT (sense) and
GGTGTTCTGTTTCTCCTTAC (antisense) for TNFR1, CCACCCATGGC
AAATTCCATGGCA (sense) and TCTAGACGGCAGGTCAGGTCCACC
Fig. 1. Effect of glutamine on renal function in cisplatin-induced nephrotoxicity. Rats
were divided into four groups. The control group (Con, n ¼ 3) was injected with saline
solution. The glutamine group (GLN, n ¼ 3) received a single injection of glutamine
(1 g/kg body weight, subcutaneously). The cisplatin group (Cis, n ¼ 7) was treated with
a single dose of cisplatin (10 mg/kg, intraperitoneally). Glutamine was injected on day
1 after cisplatin injection (CisþGLN, n ¼ 7). Blood samples were collected for mea-
surement of BUN and serum creatinine (Cr) levels on day 3 after cisplatin injection.
Data are expressed as means ± standard deviation (SD). BUN and serum creatinine
levels were signiﬁcantly improved in the CisþGLN group compared with the Cis group
(**p < 0.001).
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mal cycler according to the manufacturer's instructions. Equal vol-
umes of the ampliﬁcation products were analyzed by 1.5%-agarose
gel electrophoresis with 0.5 mg/mL of ethidium bromide staining.
2.7. Cell viability assay
Cell viabilitywas determined using theWST-1 assay. Brieﬂy, HK-2
cells (4  103 cells in 200 mL) were treated with various concentra-
tions of cisplatin or vehicle for each time point with various con-
centrations (1, 2, 5, or 10mM) of glutamine, whichwas administered
simultaneously with cisplatin treatment. WST-1 reagents, 2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazo-
lium monosodium salt and 1-methoxy-5-methylphenazinium
methylsulfate (Dojin Laboratories), were added to cells and incu-
bated for 3 h at 37 C. Using an enzyme-linked immunoabsorbent
assay autoreader, cell viability was determined by measuring the
difference between absorbances at 450 nm.
2.8. Measurement of renal GSH levels
GSH content in HK-2 cells was measured using Glutathione
Assay kits (Sigma) according to the manufacturer's instructions.
Brieﬂy, HK-2 cells were homogenized in 0.5 mL of glutathione re-
action buffer containing 0.1 mL of 5% sulfosalicylic acid. To generate
NADPH, 20 mL of NADPH Generation Mix and 140 mL of glutathione
reaction buffer was mixed and incubated at room temperature for
10 min. Next, 20 mL of either the GSH standard solution or sample
solution was added, followed by incubation at room temperature
for 5e10min and a further addition of 20 mL of substrate solution. A
microplate reader was used to measure the absorbance at 405 nm
(Molecular Devices Corp., Sunnyvale, CA).
2.9. Immunoblot analysis
Kidneys were removed and homogenized in lysis buffer (Pro-
Prep, iNtTON Biotechnology, Inc., Sungnam, Korea). Protein con-
centration was determined using the bicinchoninic acid reagent
from Pierce. Aliquots of protein extracts (60 and 20 mg, kidney tis-
sue and HK cells, respectively) were loaded in each lane for elec-
trophoresis under reducing conditions and were subsequently
electroblotted onto nitrocellulose membranes. Blots were incu-
bated in a blocking buffer containing 1% BSA and 2% fat-free milk,
and then exposed to the primary antibodies (rabbit anti-caspase-3
(Cell Signaling), OCT-2 (Santa Crutz), p-JNK (Cell Signaling), JNK
(Cell Signaling), pERK (Cell Signaling), ERK (Cell Signaling), p-p38
(Cell Signaling), p38 (Cell Signaling), p-p53 (Cell Signaling) and p53
(Cell Signaling)) overnight at 4 C. Finally, blots were incubated
with horseradish peroxidase-conjugated secondary antibody, and
antigens on the blots were detected using the enhanced chem-
iluminescence kit from Pierce.
2.10. Determination of platinum contents
100 mg of tissue sample was dissolved in 250 mL of benzetho-
nium hydroxide and incubated at 55 C overnight. An aliquot of
50 mL of solubilized tissue sample was diluted with 0.15 N HCl so-
lution to a ﬁnal volume of 5 mL. The platinum levels in tissue
samples were determined using a ICP-AES method. Tissue con-
centrations are expressed as mg platinum/g tissue.
2.11. Statistical analysis
Data are expressed as means ± SD. Statistical analyses were
conducted using the GraphPad Prism software (GraphPad Software,San Diego, CA). Data were evaluated using one-way ANOVA with
Tukey's multiple comparison test (for comparison all groups). All
statistical testes used p < 0.05 to indicate signiﬁcance.
3. Results
3.1. Glutamine protects against renal functional impairment
induced by cisplatin
Glutamine (CisþGLN) markedly protected cisplatin-treated rats
from renal function impairment, with signiﬁcantly lower BUN and
serum creatinine levels at day 3 compared with rats that received
saline (Cis) (Cis vs CisþGLN, 153 mg/dL vs 118 mg/dL, respectively;
** p < 0.001 for BUN; Cis vs CisþGLN, 2.2 mg/dL vs 1.3 mg/dL, **
p < 0.001 for serum creatinine; Fig. 1). These results indicate that
glutamine protected kidneys against cisplatin-induced nephrotox-
icity and ameliorated partially renal dysfunction.
3.2. Reduced cisplatin-induced renal tubular injury following
glutamine administration
The control (Con) and glutamine-only (GLN) groups demon-
strated no renal structural changes (Fig. 2A and B). The kidneys of
cisplatin-treated rats that received saline showed AKI-associated
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loss of brush border, debris of the intratubular and ﬂattening of the
tubular epithelium (Cis, Fig. 2A and B). Kidneys from rats that
received glutamine had fewer necrotic tubules and tubular casts
compared with kidneys from cisplatin group (CisþGLN, Fig. 2A and
B). These results show that glutamine administration protected
kidney from renal injury after cisplatin injection.
3.3. Reduced cisplatin-induced renal tubular apoptosis following
glutamine administration
A key target in cisplatin-induced AKI is the tubular epithelium,
which undergoes detachment and apoptosis. We used TUNEL
staining to investigate whether glutamine could exert anti-
apoptotic activity. The number of TUNEL-positive cells in the
tubular epithelium was signiﬁcantly increased in cisplatin-treated
rats at day 3, and the extent of cell death was signiﬁcantly
reduced in rats that had received glutamine (Fig. 3A). To strengthen
these morphological observations and further investigate the
ability of glutamine to prevent tubular apoptosis, we measured the
expression of cleaved caspase-3, as known an index of apoptosis, in
the kidney. Glutamine signiﬁcantly reduced the expression of
cleaved caspase-3 (Fig. 3B).
3.4. Reduced mRNA and protein expression of hOCT2 by glutamine
in HK cells
Cisplatin-induced nephrotoxicity is known to be mediated via
OCT2 in the human kidney (22,23). We performed western blot for
OCT2 protein expression and measured the Platinum (Pt) concen-
tration for cisplatin accumulation in the kidney at day 3 after
cisplatin injection. Expression of OCT2 was increased in cisplatin-
treated kidneys while the expression was decreased by glutamine
administration in cisplatin-treated rats (Fig. 4A). Pt concentration
was well correlated with OCT2 expression in the kidneys given to
cisplatin. High level of Pt concentration in the kidneys given to
cisplatin was signiﬁcantly reduced in glutamine-treated cisplatinFig. 2. Protective effect of glutamine on renal morphology in cisplatin-induced nephrotoxicit
cisplatin injection (A). The kidney from the glutamine group (GLN) showed a similar histolo
severe casts and distinct tubular necrosis. Kidney sections from CisþGLN rats showed mild
rats exhibited severe tubular injury in all scoring categories, whereas kidneys from rats treat
based on the percentage of affected tubules in a high-powered ﬁeld (400), as described in t
group than in the Cis group (**p < 0.001).group (Fig. 4B). These data suggest that glutamine treatment might
be involved in reduced OCT2 expression, and is thought to provide
protection against the cisplatin uptake in the kidneys.
3.5. Effect of glutamine on cisplatin-induced cell viability in HK-2
cells
Proximal tubular cell death is considered to be the main
pathophysiological event underlying cisplatin nephrotoxicity (3).
To investigate effects of glutamine in vitro, we cultured HK-2 cells.
Loss of cell viability was noted after 24 h incubations with various
concentrations of cisplatin (10, 20, 30, or 50 mM) (Fig. 5A) and
glutamine (1, 2, 5, or 10 mM) (Fig. 5B). Based on these data, 30 mM
cisplatin with 50% cell death was selected for further study. For
glutamine, 2 mM was chosen as the concentration in the con-
ventional culture medium; this concentration had no signiﬁcant
effect on the growth rate and cell morphology of HK-2 cells. To
conﬁrm the effect of 30 mM cisplatin and/or 2 mM glutamine
concentrations, cell viability was assessed in cells treated with
cisplatin plus glutamine for 24 h. Cell viability was increased
signiﬁcantly in the cisplatin plus glutamine (CisþGLN) compared
with the cisplatin alone (Cis) group (Fig. 5C). To study whether
apoptotic-like nuclear morphology was present, HK-2 cells were
treated with 30 mM cisplatin and 30 mM cisplatin plus 2 mM
glutamine for 24 h, and then stained with 40,6-diamidino-2-
phenylindole (DAPI). Nuclear fragmentation (apoptotic nuclei)
was clearly detected in cisplatin-treated cells and glutamine
treatment decreased this fragmentation (Fig. 5D). Taken together,
these results suggest that glutamine attenuated cisplatin-induced
apoptosis of proximal tubular cells.
3.6. Reduced mRNA of hOCT2 in renal tubular cells
Cisplatin is taken up into the tubular cells by OCTs (22,23). To
investigate the involvement of glutamine in the regulation of OCTs
expression, we performed RT-PCR. hOCT1 mRNA was slightly
induced by cisplatin treatment but the level was not changed byy. Hematoxylin and eosin staining was performed on sections of rat kidneys 3 days after
gy to the control kidney (Con). Kidney sections from cisplatin-treated rats (Cis) showed
casts and tubular necrosis (CisþGLN). Scale bar, 50 mm. Kidneys from cisplatin-treated
ed with glutamine plus cisplatin showed signiﬁcantly less injury (B). Injury scoring was
he Materials and methods. These injury scores were signiﬁcantly lower in the CisþGLN
Fig. 3. Protective effects of glutamine on cisplatin-induced apoptosis. Cisplatin-induced apoptosis was detected using the TUNEL assay (A). TUNEL-positive cells were stained with
dense brown spots and counted as described in the Materials and methods. The number of TUNEL-positive cells was signiﬁcantly higher in the Cis group than in the CisþGLN group
(**p < 0.001, *p < 0.01). Scale bar, 50 mm. Immunoblot analysis was performed using a speciﬁc antibody against cleaved caspase-3 (B). b-actin was used as a loading control. The blot
shown is representative of three separate experiments (Con lane, n ¼ 3/lane; GLN lane, n ¼ 3; Cis lane, n ¼ 3/lane; CisþGLN, n ¼ 3/lane). Higher expression was observed in the Cis
group compared with the CisþGLN group (**p < 0.001, zp < 0.05).
Fig. 4. Effect of glutamine on expression of cisplatin uptake-related OCT2 and on platinum concentration in the kidneys. Immunoblot analysis was performed using a speciﬁc
antibody against OCT2 (A). b-actin was used as a loading control. The blot shown is representative of three separate experiments. Higher expression was observed in the Cis group
compared with the CisþGLN group. The platinum concentration was measured using ICP-AES method in the kidney tissues (B) (**p < 0.001, *p < 0.01).
H.-J. Kim et al. / Journal of Pharmacological Sciences 127 (2015) 117e126 121glutamine and hOCT3-positive signals were quite strong but the
level was not changed by glutamine, similar to hOCT1 expression
(data not shown). Compared with hOCT1 and hOCT3 mRNA
expression, glutamine decreased level of the hOCT2 mRNA
expression induced by cisplatin (Fig. 6A). Moreover, to verify the
onset of OCT2 protein expression by cisplatin treatment, we tried to
ﬁnd the level of OCT2 protein in various times. The levels of OCT2
protein was started to induce at 60 min, peaked at 120 min, and
then downed at 24 h after cisplatin treatment. Unfortunately, our
results were also not correlated with mRNA (Fig. 6A) and protein
(Fig. 6B) levels for hOCT-2 at 24 h after cisplatin treatment. Both at60 min and 24 h, the levels seemed to decrease by glutamine but
not signiﬁcant. However, the level was signiﬁcantly reduced by
glutamine at 120 min. Thus, this result suggests that this earlier
inhibition of cisplatin uptake by glutaminemay be resulted in other
cellular signaling events such as MAPKs and p53 activation.
3.7. Effect of glutamine on GSH levels reduced by cisplatin in HK-2
cells
Because caspase-3 cleavage was actively induced by cisplatin,
we decided to study whether glutamine modiﬁed other steps
Fig. 5. Dose responses of cisplatin and glutamine in HK-2 cells and effect of glutamine on cisplatin-induced cell viability. HK-2 cells were treated with various concentrations of
cisplatin (A), glutamine (B), 30 mM cisplatin, and 30 mM cisplatin plus 2 mM glutamine for 24 h (C). Cell viability was assessed using the WST-1 assay. (D) HK-2 cells treated with
30 mM cisplatin and 30 mM cisplatin plus 2 mM glutamine were stained with DAPI to investigate apoptotic-like nuclear morphology. Data were expressed as means ± SD of three
separate experiments. Cell viability (C) was signiﬁcantly higher in the CisþGLN group than in the Cis group (**p < 0.001, zp < 0.05).
Fig. 6. Effect of glutamine on expression of cisplatin uptake-related OCT2 in HK-2 cells. HK-2 cells were cultured with 30 mM cisplatin in the presence (CisþGLN) or absence of 2 mM
glutamine (Cis) for 24 h. Expression of hOCT2 was analyzed by RT-PCR. hOCT2mRNA expression was signiﬁcantly decreased in the CisþGLN group compared with the Cis group (A).
Expression of hOCT2 protein was analyzed by immunoblot. hOCT2 protein expression was signiﬁcantly decreased in the CisþGLN group (GC and GþC) compared with the Cis group
at 120 min after cisplatin (B) (**p < 0.001, zp < 0.05).
H.-J. Kim et al. / Journal of Pharmacological Sciences 127 (2015) 117e126122upstream in the extrinsic apoptosis pathway. As an oxidative stress
index, the cellular GSH levels were measured in HK-2 cells treated
with 30 mM cisplatin for 24 h. In Fig. 7, GSH levels were decreased
by cisplatin in HK-2 cells and in the presence of glutamine, the
levels were signiﬁcantly increased.3.8. Effect of glutamine on cisplatin-induced MAPK activation in
HK-2 cells
MAPKs activation was augmented in HK-2 cells incubated with
cisplatin. Activation of JNK, ERK, and p38was signiﬁcantly higher in
H.-J. Kim et al. / Journal of Pharmacological Sciences 127 (2015) 117e126 123cisplatin-stimulated cells than in control cells. However, in cells
incubated with glutamine and cisplatin, only a slight increase was
detected despite cisplatin stimulation (Fig. 8).
3.9. Effect of glutamine on cisplatin-induced p53 activation and
upregulation of TNF-a and TNFR1 mRNA expression in HK-2 cells
The signaling pathways that lead to tubular cell apoptosis dur-
ing cisplatin treatment are complex and remain to be clariﬁed
(15,28). In rat proximal tubular cells, p53 is activated during
cisplatin treatment, and p53 inhibition by pharmacological and
molecular approaches ameliorates cisplatin-induced apoptosis
(16,29e31). To determine whether p53 was involved in the cyto-
protective effect of glutamine, we examined p53 phosphorylation
by immunoblot analysis. Activation of p53 by cisplatin was sup-
pressed when cells were treated with glutamine (Fig. 9A). The
result suggests that p53 inactivation by glutaminemay result in less
apoptotic death during cisplatin treatment. The death receptor-
mediated apoptotic pathway is involved in the pathogenesis of
cisplatin-induced AKI (32,33). The mRNA level of TNF-a increased
in the cells with 30 mM cisplatin and this increase was inhibited by
treatment with 2 mM glutamine. The mRNA level of tumor necrosis
factor receptor 1 (TNFR1) was also increased with 30 mM cisplatin
and decreased by glutamine treatment (Fig. 9B).
4. Discussion
We found that cisplatin induced a rapid loss of renal function, as
indicated by increases in BUN and serum creatinine levels, which
were partially, but signiﬁcantly, reduced in animals post-treated
with glutamine. Consistently, glutamine ameliorated tubular
damage and apoptotic cell death in renal tissues. Additionally, in
in vitro studies, we showed that glutamine attenuates cisplatin-
induced renal tubular cell injury, most likely in different ways.
Glutamine alone had no signiﬁcant effect on growth, cell conﬂu-
ence, or the monolayer morphology of HK-2 cells. According to our
results, glutamine seemed to protect tubular cells against cisplatin
toxicity in a sequential manner, initially through regulation of
cisplatin accumulation, followed by oxidative stress, and ﬁnally
through the death receptor-mediated signaling pathway.
AKI is attributed to the accumulation of cisplatin in renal
proximal tubular cells and cisplatin is known to permeate proximal
tubular cells through apical and basolateral OCTs (13,34). BothFig. 7. Effect of glutamine on the changed GSH level by cisplatin in HK-2 cells. HK-2
cells were cultured with 30 mM cisplatin in the presence (CisþGLN) or absence of
2 mM glutamine (Cis) for 24 h. To investigate oxidative stress, the GSH level was
measured as described in the Materials and methods. Data are expressed as
means ± SD. Reduced GSH level was signiﬁcantly higher in the CisþGLN group than in
the Cis group (**p < 0.001, *p < 0.01).basolateral OCT1 and OCT2 as well as Ctr1 are involved in cisplatin
transport, accumulation, and toxicity (13,22,23). In both cases,
apoptosis and accumulation of cisplatin were decreased, but not
eliminated, in the presence of competitive organic cations or
transporter knockdown (13,22,23). In particular, hOCT2 is a renal
OCT isoform and hOCT1 is a hepatic isoform in humans (20,35),
indicating that the organ-speciﬁc toxicity of cisplatin with toxic
effects is in the kidney, not in the liver. Because the nephrotoxicity
of cisplatin is caused by its uptake via OCT2, it is important whether
glutamine treatment involves changes in OCT2 expression. Gluta-
mine treatment affected OCT2 expression and cisplatin accumula-
tion in the kidneys induced by cisplatin (Fig. 4). This result was
consistent with OCT2 mRNA expression in vitro (Fig. 6) and a pre-
vious report, inwhich cisplatin interactedwith hOCT2, but not with
hOCT1 in hOCT1 and 2-transfected cells (13). We suggest the
following possibilities for a protective role of glutamine in cisplatin-
induced nephrotoxicity. 1) OCTs have been described to have a big
binding pocket with overlapping interaction domains for different
substrates (36,37). Glutamine may act either to help the binding of
a substrate or to upregulate the cellular level of a substrate that can
bind in a binding pocket of hOCT2. This can result in less cisplatin
uptake and reduced toxicity. Thus, our result suggests that gluta-
mine may play a role in the regulation of cisplatin uptake into
proximal tubular cells, although the effect is indirect to hOCT2, and
ﬁnally reduce cisplatin-induced nephrotoxicity. 2) Regulation of
OCTs may alter the secretion and absorption of multiple endoge-
nous substances, drugs, and other xenobiotics, leading to changes
in pharmacokinetics of these organic cations (38). OCTs have
several potential protein kinase phosphorylation sites in the
intracellular loops, suggesting that their activity may be subject to
regulation. Thus, glutamine may also be a factor regulating the
activity of OCTs, focused on protein kinase phosphorylation. 3)
Several signaling pathways are involved in the regulation of hOCT2-
mediated OCT (38). Whereas protein kinase A (PKA) stimulation
and activation of the G receptor-coupled signaling pathway resul-
ted in inhibition of hOCT2-mediated transport, endogenously
active Ca2þ/calmodulin (CaM) or the CaM-dependent kinases II
(CaMKII) and myosin light-chain kinase (MLCK) led to activation of
hOCT2-mediated transport. Thus, we cannot exclude the possibility
that glutamine could inhibit hOCT2-mediated transport of cisplatin
by stimulating PKA, activating the G receptor-coupled signaling
pathway, or involvement in the inactivation of endogenous active
CaM or the CaMKII and MLCK. However, these possibilities are all
hypotheses and none suggest how glutamine could be involved in
regulation of OCTs expression in cisplatin-induced nephrotoxicity.
We believe that these hypotheses will provide motivation for
further studies. As shown in Fig. 4B, our result indicates that entry
of cisplatin in the cell could be partially impaired after treatment
with glutamine. Although glutamine is not a substrate of OCT, its
administration for renal OCT2 targeting could allow the use of high-
dose cisplatin in anticancer therapywithout causing nephrotoxicity
or maintaining higher cisplatin concentrations in blood.
Both preserving the cellular GSH level and inhibiting the
reduction of the GSH level are important for the metabolic activa-
tion of cisplatin in the kidney to a more potent toxin. In the present
study, the GSH level was decreased by cisplatin treatment. This was
probably resulted in using glutathione for cisplatin to be converted
to a cisplatineglutathione conjugate through activation of GGT in
tubular cells. However, our results suggest that glutamine can
maintain glutathione at basal levels through decreasing cisplatin
uptake.
Genotoxic stress induced by cisplatin is accompanied by
oxidative stress, a widely studied phenomenon (39) and is related
to several cellular signaling activators, including MAPKs. Glutamine
certainly reduced the activation of MAPKs by cisplatin, although we
Fig. 8. Effect of glutamine on MAPKs activation on cisplatin-induced nephrotoxicity. HK-2 cells were cultured with 30 mM cisplatin in the presence (CisþGLN) or absence of 2 mM
glutamine (Cis) for 24 h. Protein expression of phosphorylated MAPKs was analyzed by immunoblotting. Phosphorylated MAPKs levels were signiﬁcantly lower in the CisþGLN
group than in the Cis group (**p < 0.001, zp < 0.05, *p < 0.01).
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stress and MAPKs activation in HK-2 cells. Additionally, cisplatin is
also related to p53 activation (40). Pharmacological and genetic
inhibition of p53 attenuates cisplatin-induced apoptosis in cultured
tubular cells (29,31). Furthermore, less renal injury is observed
when p53 is inhibited by siRNA in cisplatin-treated animals (41).
Previous studies have shown that p53 phosphorylation is induced
within 30 min of cisplatin incubation, followed by p53 stabilization
and accumulation in 2e4 h in renal proximal tubular cells (26,30).
In our study, glutamine might be involved in reducing tubular cell
apoptosis by cisplatin, as determined by decreased p53
phosphorylation.
The death receptor-mediated pathway is involved in the
pathogenesis of cisplatin-induced AKI and it has been demon-
strated that ablation of Fas and TNFR1 protects tubular cells
against cisplatin toxicity (33). Oxidative stress, including reactive
oxygen species (ROS), was especially reported to induce renal
tubular cell death through the activation of death receptor-
mediated apoptotic pathways in cisplatin-induced renal tubular
cell death (32). Whereas death receptor-mediated pathways can
be activated by ROS, several studies have reported that such
cascades can also generate ROS. Speciﬁcally, ROS can act as
second messengers during receptor-mediated apoptosis (42).
Thus, oxidative stress and death receptor-mediated apoptotic
cascades are considered to interact synergistically. Together with
reduced GSH levels, our data suggest that damage of mito-
chondrial function may be related to receptor-mediated celldeath and glutamine may ameliorate cisplatin nephrotoxicity at
these levels.
To evaluate the potential loss of the tumoricidal effect of
cisplatin caused by the presence of glutamine, we applied cisplatin
and glutamine to a tumor-derived cell line. In particular, cisplatin
caused cell death in A549 cells, a typical cell type of clinical
cisplatin use, as reﬂected in cell viability.
However, 2 mM of glutamine alone was not signiﬁcant to cell
viability as well as not to affect protection from cisplatin toxicity.
The result indicates that the protective effect of glutamine on cell
viability is speciﬁc to renal cells, compared with tumor cells.
There is only one study about effects of glutamine in cisplatin
nephrotoxicity until now. Mora et al. (43) reported that the pre-
treatment with a single dose of glutamine inhibited the increase in
renal glutathione 24 h after cisplatin injection and decreased the
lipid peroxidation observed 7 days after cisplatin. However, oral
administration of glutamine was not effective to protect the kidney
from nephrotoxicity induced by cisplatin. Thus, it is noteworthy
that cisplatin uptake, renal dysfunction, tissue damage, and tubular
cell death by glutamine was decreased in the present study.
In conclusion, we showed that glutamine attenuated cisplatin-
induced nephrotoxicity in different ways. Its contribution may
likely start with decreasing cisplatin accumulation. The present
study provides a new role for glutamine in decreasing cisplatin-
induced nephrotoxicity and glutamine could be a useful treat-
ment for patients with cisplatin-induced acute kidney injury and
cancer.
Fig. 9. Effect of glutamine on p53 phosphorylation and mRNA expression of TNF-a and TNFR1 in cisplatin-induced nephrotoxicity. HK-2 cells were cultured with 30 mM cisplatin in
the presence (CisþGLN) or absence of 2 mM glutamine (Cis) for 24 h. Protein expression of phosphorylated p53 was analyzed by immunoblotting (A). Phosphorylated p53 levels
were signiﬁcantly lower in the CisþGLN group than in the Cis group (**p < 0.001). Expression of TNF-a and TNFR1 mRNA was analyzed by RT-PCR (B). GAPDH was used as an
internal control. Levels of TNF-a and TNFR1 mRNA were signiﬁcantly lower in the CisþGLN group than in the Cis group (**p < 0.001).
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